219 related articles for article (PubMed ID: 35668275)
1. Hemolysis induced by SARS-CoV-2 mRNA vaccination in patients with paroxysmal nocturnal hemoglobinuria.
Kamura Y; Sakamoto T; Yokoyama Y; Nishikii H; Sakata-Yanagimoto M; Chiba S; Obara N
Int J Hematol; 2022 Jul; 116(1):55-59. PubMed ID: 35668275
[TBL] [Abstract][Full Text] [Related]
2. COVID-19 vaccines induce severe hemolysis in paroxysmal nocturnal hemoglobinuria.
Gerber GF; Yuan X; Yu J; Cher BAY; Braunstein EM; Chaturvedi S; Brodsky RA
Blood; 2021 Jul; 137(26):3670-3673. PubMed ID: 33945618
[No Abstract] [Full Text] [Related]
3. COVID-19 vaccination prevents a more severe course and treatment with complement inhibitors reduce worsening hemolysis during the Omicron pandemic in patients with PNH: a single-center study.
Wang L; Hu Q; Yang Y; Chen M; Yang C; Han B
Ann Med; 2023; 55(2):2274510. PubMed ID: 38163328
[TBL] [Abstract][Full Text] [Related]
4. Severe hemolytic exacerbations of Chinese PNH patients infected SARS-CoV-2 Omicron.
Yang H; Chai X; Gong Y; Zhang X; Wang L; Zhou X; Chen X; Xu J; Xu D; He G; Li J
Immun Inflamm Dis; 2023 Aug; 11(8):e966. PubMed ID: 37647437
[TBL] [Abstract][Full Text] [Related]
5. Tolerability of COVID-19 Infection and Messenger RNA Vaccination Among Patients With a History of Kawasaki Disease.
Beckley M; Olson AK; Portman MA
JAMA Netw Open; 2022 Aug; 5(8):e2226236. PubMed ID: 35960521
[TBL] [Abstract][Full Text] [Related]
6. Complement Mediated Hemolytic Anemias in the COVID-19 Era: Case Series and Review of the Literature.
Fattizzo B; Pasquale R; Bellani V; Barcellini W; Kulasekararaj AG
Front Immunol; 2021; 12():791429. PubMed ID: 34899761
[TBL] [Abstract][Full Text] [Related]
7. Paroxysmal nocturnal hemoglobinuria and the complement system: recent insights and novel anticomplement strategies.
Risitano AM
Adv Exp Med Biol; 2013; 735():155-72. PubMed ID: 23402025
[TBL] [Abstract][Full Text] [Related]
8. Association between history of SARS-CoV-2 infection and severe systemic adverse events after mRNA COVID-19 vaccination among U.S. adults.
Tompkins LK; Baggs J; Myers TR; Gee JM; Marquez PL; Kennedy SB; Peake D; Dua D; Hause AM; Strid P; Abara W; Rossetti R; Shimabukuro TT; Shay DK
Vaccine; 2022 Dec; 40(52):7653-7659. PubMed ID: 36372665
[TBL] [Abstract][Full Text] [Related]
9. Severe refractory warm autoimmune haemolytic anaemia after the SARS-CoV-2 Pfizer-BioNTech vaccine (BNT162b2 mRNA) managed with emergency splenectomy and complement inhibition with eculizumab.
Jackson EM; Harper S; Webb GJ; Thomas W
BMJ Case Rep; 2022 Aug; 15(8):. PubMed ID: 36107725
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity and tolerability of COVID-19 messenger RNA vaccines in primary immunodeficiency patients with functional B-cell defects.
Pham MN; Murugesan K; Banaei N; Pinsky BA; Tang M; Hoyte E; Lewis DB; Gernez Y
J Allergy Clin Immunol; 2022 Mar; 149(3):907-911.e3. PubMed ID: 34952033
[TBL] [Abstract][Full Text] [Related]
11. Achievements and limitations of complement inhibition by eculizumab in paroxysmal nocturnal hemoglobinuria: the role of complement component 3.
Risitano AM; Perna F; Selleri C
Mini Rev Med Chem; 2011 Jun; 11(6):528-35. PubMed ID: 21561403
[TBL] [Abstract][Full Text] [Related]
12. The Effect of Respiratory Viral Infections on Breakthrough Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria.
Lazana I; Apap Mangion S; Babiker S; Large J; Trikha R; Zuckerman M; Gandhi S; Kulasekararaj AG
Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298309
[TBL] [Abstract][Full Text] [Related]
13. COVID-19 and Immune-Mediated RBC Destruction.
Jacobs JW; Booth GS
Am J Clin Pathol; 2022 Jun; 157(6):844-851. PubMed ID: 34919640
[TBL] [Abstract][Full Text] [Related]
14. SARS-CoV-2 vaccination and myocarditis or myopericarditis: population based cohort study.
Husby A; Hansen JV; Fosbøl E; Thiesson EM; Madsen M; Thomsen RW; Sørensen HT; Andersen M; Wohlfahrt J; Gislason G; Torp-Pedersen C; Køber L; Hviid A
BMJ; 2021 Dec; 375():e068665. PubMed ID: 34916207
[TBL] [Abstract][Full Text] [Related]
15. Clinical characteristics of 512 eculizumab-naive paroxysmal nocturnal hemoglobinuria patients in China: a single-center observational study.
Du Y; Yang Y; Yang C; Chen M; Han B
Hematology; 2022 Dec; 27(1):113-121. PubMed ID: 35068377
[TBL] [Abstract][Full Text] [Related]
16. Incidence of Cerebral Venous Thrombosis Following SARS-CoV-2 Infection vs mRNA SARS-CoV-2 Vaccination in Singapore.
Tu TM; Yi SJ; Koh JS; Saffari SE; Hoe RHM; Chen GJ; Chiew HJ; Tham CH; Seet CYH; Yong MH; Yong KP; Hui AC; Fan BE; Tan BY; Quek AML; Seet RCS; Yeo LLL; Tan K; Thirugnanam UN
JAMA Netw Open; 2022 Mar; 5(3):e222940. PubMed ID: 35297971
[TBL] [Abstract][Full Text] [Related]
17. Seroconversion after anti-SARS-CoV-2 mRNA vaccinations among moderate-to-severe psoriatic patients receiving systemic biologicals-Prospective observational cohort study.
Piros ÉA; Cseprekál O; Görög A; Hidvégi B; Medvecz M; Szabó Z; Olajos F; Barabás E; Galajda N; Miheller P; Holló P
Dermatol Ther; 2022 May; 35(5):e15408. PubMed ID: 35218276
[TBL] [Abstract][Full Text] [Related]
18. Incidence and Characteristics of Delayed Injection Site Reaction to the mRNA-1273 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine (Moderna) in a Cohort of Hospital Employees.
Jacobson MA; Zakaria A; Maung Z; Hart C; McCalmont TH; Fassett M; Amerson E
Clin Infect Dis; 2022 Mar; 74(4):591-596. PubMed ID: 34086881
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of mRNA vaccines and waning of protection against SARS-CoV-2 infection and severe covid-19 during predominant circulation of the delta variant in Italy: retrospective cohort study.
Fabiani M; Puopolo M; Morciano C; Spuri M; Spila Alegiani S; Filia A; D'Ancona F; Del Manso M; Riccardo F; Tallon M; Proietti V; Sacco C; Massari M; Da Cas R; Mateo-Urdiales A; Siddu A; Battilomo S; Bella A; Palamara AT; Popoli P; Brusaferro S; Rezza G; Menniti Ippolito F; Pezzotti P;
BMJ; 2022 Feb; 376():e069052. PubMed ID: 35144968
[TBL] [Abstract][Full Text] [Related]
20. Case report: Transfusion independence and abolition of extravascular hemolysis in a PNH patient treated with pegcetacoplan.
Fattizzo B; Versino F; Zaninoni A; Marcello APML; Vercellati C; Artuso S; Barcellini W
Front Immunol; 2022; 13():1060923. PubMed ID: 36532073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
